StockNews.com began to cover the shares of AcelRx Pharmaceuticals (NASDAQ: ACRX – Get a rating) in a report released Saturday. The company has set a “sell” rating on the specialty pharmaceutical company’s shares.
Other analysts have also recently published research reports on the stock. Cantor Fitzgerald reiterated an “overweight” rating on AcelRx Pharmaceuticals shares in a Friday, March 11 research note. Zacks Investment Research cut shares of AcelRx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday. Finally, HC Wainwright downgraded shares of AcelRx Pharmaceuticals from a “buy” rating to a “neutral” rating in a Monday, March 14 research report.
Shares of ACRX Stock opened at $0.26 on Friday. The stock has a market capitalization of $37.51 million, a P/E ratio of -0.94 and a beta of 0.70. The company has a fifty-day moving average price of $0.27 and a two-hundred-day moving average price of $0.45. AcelRx Pharmaceuticals has a 1-year low of $0.16 and a 1-year high of $1.67.
AcelRx Pharmaceuticals (NASDAQ: ACRX – Get a rating) last announced its quarterly results on Monday, May 16. The specialty pharma company reported ($0.06) EPS for the quarter, meeting analyst consensus estimates of ($0.06). In the same quarter last year, the company posted ($0.08) earnings per share. On average, research analysts expect AcelRx Pharmaceuticals to post EPS of -0.22 for the current fiscal year.
Several institutional investors and hedge funds have recently changed their holdings in the company. Rock Springs Capital Management LP increased its position in shares of AcelRx Pharmaceuticals by 0.8% in the third quarter. Rock Springs Capital Management LP now owns 3,819,402 shares of the specialty pharmaceutical company valued at $3,896,000 after purchasing an additional 30,645 shares during the period. DE Shaw & Co. Inc. increased its position in AcelRx Pharmaceuticals by 12.3% during the fourth quarter. DE Shaw & Co. Inc. now owns 3,721,586 shares of the specialty pharmaceutical company worth $2,085,000 after acquiring an additional 407,507 shares during the period. Values First Advisors Inc. increased its position in AcelRx Pharmaceuticals by 23.7% during the first quarter. Values First Advisors Inc. now owns 642,515 shares of the specialty pharmaceutical company worth $183,000 after acquiring an additional 123,241 shares during the period. Millennium Management LLC increased its position in AcelRx Pharmaceuticals by 40.1% during the fourth quarter. Millennium Management LLC now owns 334,248 shares of the specialty pharmaceutical company worth $187,000 after acquiring an additional 95,716 shares during the period. Finally, Mercer Global Advisors Inc. ADV bought a new position in AcelRx Pharmaceuticals during the third quarter worth approximately $143,000. 23.12% of the stock is currently held by institutional investors.
About AcelRx Pharmaceuticals (Get a rating)
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, is focused on developing and commercializing therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate to severe acute pain. The company is developing ZALVISO, a pre-programmed, patient-controlled analgesia system that allows hospitalized patients with moderate to severe acute pain to self-administer sufentanil sublingual tablets to manage their pain; ARX-02, which is in a Phase 2 clinical trial for the treatment of cancer-related breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures.
Get news and reviews for AcelRx Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.